At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Closed 09-28 16:00:00 EDT
23.58
+1.00
+4.43%
盘后23.58
+0.000.00%
19:30 EDT
High24.21Low22.25Vol2.06M
Open22.50D1 Closing22.58Amplitude8.68%
Mkt Cap2.82BTradable Cap2.14BTotal Shares119.54M
T/O48.56MT/O Rate2.27%Tradable Shares90.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco
Reuters  ·  09-22
Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
TIPRANKS  ·  09-22
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
MT Newswires Live  ·  09-21
NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-08
NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
TIPRANKS  ·  09-08
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
Why the Dow is Being Dragged Down by a Swiss Company's Bad News
Dow Jones  ·  09-08
Why the Dow is Being Dragged Down by a Swiss Company's Bad News
Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs
Reuters  ·  09-07
Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs
Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Reuters  ·  09-04
Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each
Reuters  ·  09-04
NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each
NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026
Reuters  ·  08-26
NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026
NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million
Reuters  ·  08-26
NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million
NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
Reuters  ·  08-15
NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Reuters  ·  08-15
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  08-08
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires
Reuters  ·  08-07
NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-06
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  08-06
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-05
NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary
Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe
Reuters  ·  08-05
Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
Benzinga Earnings  ·  08-05
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate

Introduction

Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--